IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 6, Issue 1 (2025)
J Clinic Care Skill 2025, 6(1): 47-55 |
Back to browse issues page
Article Type:
Subject:
Ethics code: IR.YUMS.REC.1399.199
History
Received: 2025/01/21 | Accepted: 2025/03/15 | Published: 2025/03/18
Received: 2025/01/21 | Accepted: 2025/03/15 | Published: 2025/03/18
How to cite this article
Gholami D, Abbasi Larki R, Manzuri L, Taheri T, Asfaram A, Sadeghi Mansourkhani H et al . Effect of Oral L-Carnitine and Omega-3 on Lipid Profiles, Sleep Quality, and Quality of Life in Hemodialysis Patients. J Clinic Care Skill 2025; 6 (1) :47-55
URL: http://jccs.yums.ac.ir/article-1-308-en.html
URL: http://jccs.yums.ac.ir/article-1-308-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
D. Gholami1, R. Abbasi Larki1, L. Manzuri2, T. Taheri3, A. Asfaram4, H. Sadeghi Mansourkhani *4, A. Dehghan5
1- Department of Nephrology, Faculty of Medical School, Yasuj University of Medical Sciences, Yasuj, Iran
2- Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- Department of Medical-Surgical Nursing, Faculty of Nursing, Yasuj University of Medical Science, Yasuj, Iran
4- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
5- Student Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran
2- Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- Department of Medical-Surgical Nursing, Faculty of Nursing, Yasuj University of Medical Science, Yasuj, Iran
4- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
5- Student Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran
Abstract (249 Views)
Aims: This study aimed to evaluate the possible beneficial effects of omega-3 and L-carnitine, as well as their combination, on individuals undergoing hemodialysis.
Materials & Methods: This randomized clinical trial was conducted on 75 hemodialysis patients, divided into three groups (each 25 participants) using a randomized block method. The intervention groups received L-carnitine 250 mg tablets twice a day, one omega-3 capsule, 1000 mg per day, and L-carnitine 250 mg tablets twice a day along with one omega-3 capsule, 1000 mg per day, for three months. Lipid profiles and C-reactive protein levels were measured through laboratory tests before and after the intervention. The quality of life for kidney disease and quality of sleep were assessed using the Kidney Disease Quality of Life Questionnaire and the Pittsburgh Sleep Quality Index, respectively. Data were analyzed using SPSS 20 software.
Findings: The administration of L-carnitine (500 mg per day) did not demonstrate a beneficial effect on high-density lipoprotein, low-density lipoprotein, triglyceride, and C-reactive protein serum levels (p>0.05), but it improved the quality of sleep. Omega-3 supplementation (1000 mg per day) decreased triglyceride and low-density lipoprotein levels, although these reductions were not significant. Additionally, omega-3 treatment significantly improved the quality of life in kidney disease and the quality of sleep in patients undergoing hemodialysis (p<0.05). The coadministration of L-carnitine with omega-3 did not show superior effects compared to omega-3 alone in the evaluated parameters.
Conclusion: Omega-3 supplementation, both alone and in combination with L-carnitine, improves the quality of sleep and life in hemodialysis patients.
Materials & Methods: This randomized clinical trial was conducted on 75 hemodialysis patients, divided into three groups (each 25 participants) using a randomized block method. The intervention groups received L-carnitine 250 mg tablets twice a day, one omega-3 capsule, 1000 mg per day, and L-carnitine 250 mg tablets twice a day along with one omega-3 capsule, 1000 mg per day, for three months. Lipid profiles and C-reactive protein levels were measured through laboratory tests before and after the intervention. The quality of life for kidney disease and quality of sleep were assessed using the Kidney Disease Quality of Life Questionnaire and the Pittsburgh Sleep Quality Index, respectively. Data were analyzed using SPSS 20 software.
Findings: The administration of L-carnitine (500 mg per day) did not demonstrate a beneficial effect on high-density lipoprotein, low-density lipoprotein, triglyceride, and C-reactive protein serum levels (p>0.05), but it improved the quality of sleep. Omega-3 supplementation (1000 mg per day) decreased triglyceride and low-density lipoprotein levels, although these reductions were not significant. Additionally, omega-3 treatment significantly improved the quality of life in kidney disease and the quality of sleep in patients undergoing hemodialysis (p<0.05). The coadministration of L-carnitine with omega-3 did not show superior effects compared to omega-3 alone in the evaluated parameters.
Conclusion: Omega-3 supplementation, both alone and in combination with L-carnitine, improves the quality of sleep and life in hemodialysis patients.
Keywords:
References
1. Ghiasi B, Nazari H, Babarabiei MA, Raiesifar A. Prevalence and causes of chronic kidney disease in patients referred to the nephrology clinic in Ilam. J Ilam Univ Med Sci. 2023;31(1):52-9. [Persian] [Link]
2. Bouya S, Balouchi A, Rafiemanesh H, Hesaraki M. Prevalence of chronic kidney disease in Iranian general population: A meta-analysis and systematic review. Ther Apher Dial. 2018;22(6):594-9. [Link] [DOI:10.1111/1744-9987.12716]
3. Bakhshayeshkaram M, Roozbeh J, Heydari ST, Honarvar B, Dabbaghmanesh MH, Ghoreyshi M, et al. A population-based study on the prevalence and risk factors of chronic kidney disease in the adult population of Shiraz, Southern Iran. Galen Med J. 2019;8:e935. [Link] [DOI:10.31661/gmj.v8i0.935]
4. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52. [Link] [DOI:10.1016/S0140-6736(16)32064-5]
5. Lee Y, Park S, Lee S, Kim Y, Kang MW, Cho S, et al. Lipid profiles and risk of major adverse cardiovascular events in CKD and diabetes: A nationwide population-based study. PLoS One. 2020;15(4):e0231328. [Link] [DOI:10.1371/journal.pone.0231328]
6. Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14(12):727-49. [Link] [DOI:10.1038/s41581-018-0072-9]
7. Kuma A, Uchino B, Ochiai Y, Kawashima M, Enta K, Tamura M, et al. Impact of low-density lipoprotein cholesterol on decline in estimated glomerular filtration rate in apparently healthy young to middle-aged working men. Clin Exp Nephrol. 2018;22(1):15-27. [Link] [DOI:10.1007/s10157-017-1407-8]
8. Zuo PY, Chen XL, Liu YW, Zhang R, He XX, Liu CY. Non-HDL-cholesterol to HDL-cholesterol ratio as an independent risk factor for the development of chronic kidney disease. Nutr Metab Cardiovasc Dis. 2015;25(6):582-7. [Link] [DOI:10.1016/j.numecd.2015.03.003]
9. Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int. 2016;89(4):886-96. [Link] [DOI:10.1016/j.kint.2015.12.034]
10. Li J, Chen J, Lan HY, Tang Y. Role of C-reactive protein in kidney diseases. Kidney Dis. 2022;9(2):73-81. [Link] [DOI:10.1159/000528693]
11. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66(3):1212-20. [Link] [DOI:10.1111/j.1523-1755.2004.00812.x]
12. Cheng E, Evangelidis N, Guha C, Hanson CS, Unruh M, Wilkie M, et al. Patient experiences of sleep in dialysis: Systematic review of qualitative studies. Sleep Med. 2021;80:66-76. [Link] [DOI:10.1016/j.sleep.2021.01.019]
13. Eloot S, Holvoet E, Dequidt C, Maertens SJ, Vanommeslaeghe F, Van Biesen W. The complexity of sleep disorders in dialysis patients. Clin Kidney J. 2021;14(9):2029-36. [Link] [DOI:10.1093/ckj/sfaa258]
14. Liu HX, Lin J, Lin XH, Wallace L, Teng S, Zhang SP, et al. Quality of sleep and health-related quality of life in renal transplant recipients. Int J Clin Exp Med. 2015;8(9):16191-8. [Link]
15. Hussien H, Apetrii M, Covic A. Health-related quality of life in patients with chronic kidney disease. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):43-54. [Link] [DOI:10.1080/14737167.2021.1854091]
16. Boudreau JE, Dubé A. Quality of life in end stage renal disease: A concept analysis. CANNT J. 2014;24(1):12-20. [Link]
17. Jesus NM, Souza GF, Mendes-Rodrigues C, Almeida Neto OP, Rodrigues DDM, Cunha CM. Quality of life of individuals with chronic kidney disease on dialysis. J Bras Nefrol. 2019;41(3):364-74. [Link] [DOI:10.1590/2175-8239-jbn-2018-0152]
18. Kuwasawa-Iwasaki M, Io H, Muto M, Ichikawa S, Wakabayashi K, Kanda R, et al. Effects of L-carnitine supplementation in patients receiving hemodialysis or peritoneal dialysis. Nutrients. 2020;12(11):3371. [Link] [DOI:10.3390/nu12113371]
19. Csiky B, Bene J, Wittmann I, Sulyok E, Melegh B. Effect of hemodialysis session on the dynamics of carnitine ester profile changes in L-carnitine pretreated end-stage renal disease patients. Int Urol Nephrol. 2013;45(3):847-55. [Link] [DOI:10.1007/s11255-012-0209-x]
20. Moeinzadeh F, Shahidi S, Mortazavi M, Dolatkhah S, Kajbaf M, Haghjooy Javanmard S, et al. Effects of omega-3 fatty acid supplementation on serum biomarkers, inflammatory agents, and quality of life of patients on hemodialysis. Iran J Kidney Dis. 2016;10(6):381-7. [Link]
21. Dashti-Khavidaki S, Gharekhani A, Khatami MR, Miri ES, Khalili H, Razeghi E, et al. Effects of omega-3 fatty acids on depression and quality of life in maintenance hemodialysis patients. Am J Ther. 2014;21(4):275-87. [Link] [DOI:10.1097/MJT.0000000000000078]
22. Katalinic L, Krtalic B, Jelakovic B, Basic-Jukic N. The unexpected effects of L-carnitine supplementation on lipid metabolism in hemodialysis patients. Kidney Blood Press Res. 2018;43(4):1113-20. [Link] [DOI:10.1159/000491807]
23. Semeniuk J, Shalansky KF, Taylor N, Jastrzebski J, Cameron EC. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients. Clin Nephrol. 2000;54(6):470-7. [Link]
24. Emami Naini A, Moradi M, Mortazavi M, Amini Harandi A, Hadizadeh M, Shirani F, et al. Effects of oral L‐carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: A randomized, double‐blinded, placebo‐controlled trial. J Nutr Metab. 2012;2012(1):510483. [Link] [DOI:10.1155/2012/510483]
25. Miyagawa T, Kawamura H, Obuchi M, Ikesaki A, Ozaki A, Tokunaga K, et al. Effects of oral L-carnitine administration in narcolepsy patients: A randomized, double-blind, cross-over and placebo-controlled trial. PLoS One. 2013;8(1):e53707. [Link] [DOI:10.1371/journal.pone.0053707]
26. Estaji Z, Jafari B, Rakhshani M, Hatami M. Effect of oral L-carnitine supplementation on sleep quality in hemodialysis patients. J Sabzevar Univ Med Sci. 2015;22(2):427-35. [Persian] [Link]
27. Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol. 2006;1(2):182-92. [Link] [DOI:10.2215/CJN.00740805]
28. Lin YL, Wang CL, Liu KL, Yeh CN, Chiang TI. Omega-3 fatty acids improve chronic kidney disease-associated pruritus and inflammation. Medicina. 2022;58(6):796. [Link] [DOI:10.3390/medicina58060796]
29. Shen T, Xing G, Zhu J, Zhang S, Cai Y, Li D, et al. Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol. Lipids Health Dis. 2017;16(1):253. [Link] [DOI:10.1186/s12944-017-0617-0]
30. Musazadeh V, Alinejad H, Esfahani NK, Kavyani Z, Keramati M, Roshanravan N, et al. The effect of L-carnitine supplementation on lipid profile in adults: An umbrella meta-analysis on interventional meta-analyses. Front Nutr. 2023;10:1214734. [Link] [DOI:10.3389/fnut.2023.1214734]
31. Karimi M, Pirzad S, Pourfaraji SMA, Parhizkar Roudsari P, Shirsalimi N, Ahmadizad S. Effects of L-carnitine supplementation on lipid profile in adult patients under hemodialysis: A systematic review and meta-analysis of RCTs. Front Med. 2024;11:1454921. [Link] [DOI:10.3389/fmed.2024.1454921]
32. Zhang C, Ge C, Wang J, Sun D. Effects of fish oil during hemodialysis on nutritional status and quality of life: A randomized double-blinded trial. Food Nutr Res. 2020;64. [Link] [DOI:10.29219/fnr.v64.4450]
33. Dai Y, Liu J. Omega-3 long-chain polyunsaturated fatty acid and sleep: A systematic review and meta-analysis of randomized controlled trials and longitudinal studies. Nutr Rev. 2021;79(8):847-68. [Link] [DOI:10.1093/nutrit/nuaa103]
34. Martínez-Majolero V, Urosa B, Hernández-Sánchez S, Arroyo D. The moderating role of health variables on the association between physical exercise and quality of life in patients with end-stage renal disease. Healthcare. 2023;11(15):2148. [Link] [DOI:10.3390/healthcare11152148]
35. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994;3(5):329-38. [Link] [DOI:10.1007/BF00451725]
36. Fardinmehr O, Farajzadegan Z, Emami Naini A, Mortazavi M, Gholamrezaei A. The validity and reliability of the Persian version of kidney disease quality of life questionnaire-short form (KDQOL-SF) in Iranian patients. J Isfahan Med Sch. 2012;29(165):2159-68. [Link]
37. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213. [Link] [DOI:10.1016/0165-1781(89)90047-4]
38. Farrahi Moghaddam J, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P). Sleep Breath. 2012;16(1):79-82. [Link] [DOI:10.1007/s11325-010-0478-5]
39. Chen Y, Abbate M, Tang L, Cai G, Gong Z, Wei R, et al. L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: A systematic review and meta-analysis. Am J Clin Nutr. 2014;99(2):408-22. [Link] [DOI:10.3945/ajcn.113.062802]
40. Wagner S, Merkling T, Metzger M, Koppe L, Laville M, Boutron-Ruault MC, et al. Probiotic intake and inflammation in patients with chronic kidney disease: An analysis of the CKD-REIN cohort. Front Nutr. 2022;9:772596. [Link] [DOI:10.3389/fnut.2022.772596]
41. De Lima K, Mazur CE, Vicente Cavagnari MA, Castilho AJ, Schiessel DL. Omega-3 supplementation effects on cardiovascular risk and inflammatory profile in chronic kidney disease patients in hemodialysis treatment: An intervention study. Clin Nutr ESPEN. 2023;58:144-51. [Link] [DOI:10.1016/j.clnesp.2023.09.914]
42. Keshani M, Alikiaii B, Babaei Z, Askari G, Heidari Z, Sharma M, et al. The effects of L-carnitine supplementation on inflammation, oxidative stress, and clinical outcomes in critically Ill patients with sepsis: A randomized, double-blind, controlled trial. Nutr J. 2024;23(1):31. [Link] [DOI:10.1186/s12937-024-00934-4]
43. Rastgoo S, Fateh ST, Nikbaf-Shandiz M, Rasaei N, Aali Y, Zamani M, et al. The effects of L-carnitine supplementation on inflammatory and anti-inflammatory markers in adults: A systematic review and dose-response meta-analysis. Inflammopharmacology. 2023;31(5):2173-99. [Link] [DOI:10.1007/s10787-023-01323-9]
44. Sahebkar A. Effect of L-carnitine supplementation on circulating C-reactive protein levels: A systematic review and meta-analysis. J Med Biochem. 2015;34(2):151-9. [Link] [DOI:10.2478/jomb-2014-0030]
45. Haghighatdoost F, Jabbari M, Hariri M. The effect of L-carnitine on inflammatory mediators: A systematic review and meta-analysis of randomized clinical trials. Eur J Clin Pharmacol. 2019;75(8):1037-46. [Link] [DOI:10.1007/s00228-019-02666-5]
46. Heydarbaki M, Amerian M, Abbasi A, Amanpour F, Mohammadpourhodki R, Ebrahimi H. The effects of omega-3 on the sleep quality of patients with uremic pruritus undergoing hemodialysis: A randomized crossover study. J Complement Integr Med. 2020;18(1):217-22. [Link] [DOI:10.1515/jcim-2019-0081]